Episode 5: A Literature Review of TRT on Cardiovascular Disease and Prostate Cancer

SummaryIn this conversation, Jackie Tewes delves into the critical topics of testosterone's impact on cardiovascular health and prostate cancer. She discusses the findings from various studies, including the Traverse Trial, which indicate that testosterone replacement therapy is safe and may even provide protective benefits for men with cardiovascular risks. She also addresses common myths surrounding testosterone and prostate cancer, emphasizing that current research does not support the notion that testosterone therapy increases cancer risk. The discussion aims to provide clarity and evidence-based insights for men considering testosterone therapy as part of their health management.TakeawaysTestosterone replacement therapy is safe for men with cardiovascular disease.The Traverse Trial showed no significant cardiovascular risks with testosterone therapy.Testosterone therapy may lower the risk of major cardiovascular events.Studies indicate testosterone can improve sexual function and mood.Research does not support the idea that testosterone causes prostate cancer growth.Long-term testosterone therapy is associated with lower mortality rates.Men with low testosterone levels may have a higher risk of aggressive prostate cancer.Testosterone therapy does not increase the risk of prostate cancer recurrence.The saturation model explains why testosterone does not promote prostate cancer growth.Current literature supports the safety of testosterone therapy in men with a history of prostate cancer.Prostate Cancer Articles1. Morgentaler, Abraham. "Testosterone and Prostate Cancer: An Historical Perspective on a Modern Myth." European Association of Urology. June 26, 2006.2. Khera, Mohit, et. al. "A New Era of Testosterone and Prostate Cancer: From Physiology to Clinical Implications." European Association of Urology. August 7, 2013.3. Loeb, Stacy, et. al. "Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer." Journal of Clinical Oncology, vol. 35, no. 13. May 1, 2017.